Smith & Nephew (SN.) Short Positions
Add to Alert list

Active Short Positions

Holder Position Change Date
Marshall Wace LLP 0.9% 0 10-Dec-2024 View History
Kintbury Capital LLP 0.51% 0 20-Nov-2024 View History
WorldQuant LLC 0.5% 0 20-Nov-2024 View History
Greenvale Capital LLP 0.74% 0 23-Oct-2024 View History
AKO Capital LLP 1.22% 0 15-Oct-2024 View History
Citadel Advisors LLC 0.51% 0 02-Aug-2024 View History

Historical Short Positions

Holder Position Change (%) Date
Marshall Wace LLP 0.5% 27-Oct-2020 View History
Marshall Wace LLP 0.49% 01-Oct-2020 View History
Marshall Wace LLP 0.51% 22-Sep-2020 View History
Marshall Wace LLP 0.48% 15-Jul-2020 View History
Marshall Wace LLP 0.51% 08-Jul-2020 View History
Marshall Wace LLP 0.49% 06-Jul-2020 View History
Marshall Wace LLP 0.51% 01-Jul-2020 View History
Marshall Wace LLP 0.48% 08-Apr-2020 View History
Marshall Wace LLP 0.52% 06-Apr-2020 View History
Marshall Wace LLP 0.69% 02-Apr-2020 View History
Marshall Wace LLP 0.76% 30-Mar-2020 View History
Marshall Wace LLP 0.88% 26-Mar-2020 View History
Marshall Wace LLP 0.99% 17-Mar-2020 View History
Marshall Wace LLP 1.01% 16-Mar-2020 View History
Marshall Wace LLP 0.95% 13-Mar-2020 View History
Marshall Wace LLP 0.88% 11-Mar-2020 View History
Marshall Wace LLP 0.79% 10-Mar-2020 View History
Marshall Wace LLP 0.6% 06-Mar-2020 View History

Smith & Nephew is a British medical technology company that develops, manufactures, and sells medical devices. Products include arthroscopy, trauma, clinical therapy, and orthopaedic reconstruction products. Smith & Nephew's products are sold in over 100 countries, including Europe, the Americas, Asia Pacific, the Middle East, and Africa.

Smith & Nephew operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.

Smith & Nephew's shares are traded in London and New York, and the company is a constituent of the UK's FTSE100.

Smith and Nephew share price launched at 182p in 1988.

Note: This description is in part generated by AI and not an endorsement by or the opinion of Investegate
UK 100